We are live on ! Find out more
RGLS

Regulus Therapeutics

Delisted

RGLS was delisted on the 24th of June, 2025.

75 hedge funds and large institutions have $107M invested in Regulus Therapeutics in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 28 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

968% more call options, than puts

Call options by funds: $299K | Put options by funds: $28K

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

27% more capital invested

Capital invested by funds: $84.5M → $107M (+$22.4M)

9% more funds holding

Funds holding: 6975 (+6)

0.67% more ownership

Funds ownership: 81.69%82.36% (+0.67%)

39% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 28

Holders
75
Holders Change
+6
Holders Change %
+8.7%
% of All Funds
1.01%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
17
Reduced
28
Closed
8
Calls
$299K
Puts
$28K
Net Calls
+$271K
Net Calls Change
+$244K
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
76
Millennium Management
New York
-$3.46M -2,192,158 Closed
Adage Capital Partners
77
Adage Capital Partners
Massachusetts
-$3.16M -2,000,000 Closed
RCM
78
RA Capital Management
Massachusetts
-$532K -336,843 Closed
PEAK6
79
PEAK6
Illinois
-$94.8K -60,000 Closed
Two Sigma Investments
80
Two Sigma Investments
New York
-$35.2K -22,264 Closed
Commonwealth Equity Services
81
Commonwealth Equity Services
Massachusetts
-$18K -11,700 Closed
CA
82
Continuum Advisory
Idaho
-$474 -300 Closed

RGLS Hedge Fund Activity: Q1 2025 in Review

75 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2025, worth a combined $107M — up 27% from $84.5M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new RGLS positions and 8 closed out — a net gain of 6 holders — while 17 added to existing stakes and 28 trimmed.

The largest buyer was Federated Hermes, adding an estimated $3.92M. The largest seller was Millennium Management, exiting entirely with an estimated $3.46M sold.

  • 75 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2025, up from 69 in Q4 2024.
  • Funds reported $107M of Regulus Therapeutics stock for Q1 2025, up 27% quarter-over-quarter.
  • 14 funds opened new Regulus Therapeutics positions in Q1 2025 and 8 closed out, a net change of +6 holders.
  • The largest Regulus Therapeutics buyer in Q1 2025 was Federated Hermes, an estimated $3.92M added.
  • The largest Regulus Therapeutics seller in Q1 2025 was Millennium Management, an estimated $3.46M sold.

Based on aggregated 13F filings for Q1 2025.